Edition:
United States

Solid Biosciences Inc (SLDB.OQ)

SLDB.OQ on NASDAQ Stock Exchange Global Select Market

42.07USD
22 Jun 2018
Change (% chg)

-- (--)
Prev Close
$42.07
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
101,740
52-wk High
$54.51
52-wk Low
$6.83

Chart for

About

Solid Biosciences Inc., formerly Solid Biosciences, LLC, is a life science company. The Company is focused on developing therapies for duchenne muscular dystrophy (DMD). It is developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its corrective therapies... (more)

Overall

Beta: --
Market Cap(Mil.): $1,491.89
Shares Outstanding(Mil.): 35.46
Dividend: --
Yield (%): --

Financials

  SLDB.OQ Industry Sector
P/E (TTM): -- 248.83 34.14
EPS (TTM): -1.67 -- --
ROI: -48.73 -5.25 13.10
ROE: -70.33 -6.83 15.09

BRIEF-Boxer Capital Reports 6.2 Pct Passive Stake In Solid Biosciences

* BOXER CAPITAL, LLC REPORTS 6.2 PERCENT PASSIVE STAKE IN SOLID BIOSCIENCES INC AS OF MAY 9 - SEC FILING Source text: (https://bit.ly/2GwS8zg) Further company coverage:

May 18 2018

BRIEF-Solid Biosciences Reports Quarterly Loss Per Share Of $0.54

* SOLID BIOSCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 10 2018

BRIEF-Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy

* SOLID BIOSCIENCES PROVIDES UPDATE ON SGT-001 CLINICAL DEVELOPMENT PROGRAM FOR DUCHENNE MUSCULAR DYSTROPHY

Apr 18 2018

BRIEF-Solid Biosciences Reports Full Year 2017 Financial Results And Provides Corporate Update

* SOLID BIOSCIENCES REPORTS FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 29 2018

BRIEF-Solid Biosciences Announces Clinical Hold On SGT-001 Phase I/Ii Clinical Trial

* SOLID BIOSCIENCES ANNOUNCES CLINICAL HOLD ON SGT-001 PHASE I/II CLINICAL TRIAL FOR DUCHENNE MUSCULAR DYSTROPHY

Mar 14 2018

BRIEF-Solid Biosciences Says Now Sees IPO Of 7 Mln Shares Of Common Stock Priced Between $18-$19/Shr - SEC Filing

* SOLID BIOSCIENCES LLC SAYS NOW SEES IPO OF 7.0 MILLION SHARES OF COMMON STOCK PRICED BETWEEN $18.00 AND $19.00 PER SHARE - SEC FILING

Jan 24 2018

Earnings vs. Estimates